Background
In 2011, the European Society of Cardiology (ESC) published its first guidance on the management of cardiovascular disease in pregnancy. 1 Since then, the literature regarding pregnancy and cardiac disease has grown, predominantly due to the work of large collaborative groups from Europe, America and Canada. Some of these studies have highlighted important obstetric issues, such as showing no benefit of elective caesarean section over vaginal delivery in women with heart disease, 2 but robust data on the management of labour in this group of high-risk women are still lacking. This is disappointing because women with cardiac disease encounter greater obstetric morbidity, in particular greater rates of postpartum haemorrhage (PPH), as well as greater rates of intervention around the time of delivery. 3, 4 As clinicians planning delivery in women with cardiac disease, we recognise that different cardiac conditions carry different risks and make detailed plans to mitigate these risks at the time of delivery. In this commentary, we focus predominately on the management of labour, particularly the second stage of labour, and consider both the evidence regarding the use of uterotonic agents in the third stage and the recent guidance regarding antibiotic prophylaxis.
Second stage of labour
In women with heart disease, epidural anaesthesia is commonly used to mitigate large fluctuations in maternal heart rate and blood pressure associated with the pain of uterine contractions. In women with an epidural, but without heart disease, prolonging the passive phase of the second stage shortens the active phase by an average of 20 minutes and may increase the chance of a spontaneous vaginal delivery; 5 on this basis, the ESC advises a prolonged passive phase. 1 In practice, a shortened active phase of the second stage is also commonly employed to reduce the cardiovascular stress of repeated Valsalva manoeuvres and the potential associated complications. Interestingly, the ESC makes no comment on active pushing, but highlights that it may be potentially undesirable by raising the possibility of avoiding 'the unwanted effects of the Valsalva manoeuvre'. However, it is not clear what these unwanted effects are. Outside of pregnancy, the Valsalva has quite marked effects on blood pressure and heart rate; during pregnancy, active pushing during a contraction is associated with a 30% increase in the heart rate. 6 In women with heart disease, repeated Valsalva manoeuvres may cause hypotension and this may be of concern in those with a Fontan repair for example, but this has not been evaluated. Despite these changes and concerns, there is no evidence that the active phase of the second stage is associated with any adverse cardiovascular effects. Indeed, data from ROPAC suggest that the risk of arrhythmia is not increased during labour and that the risk of women developing heart failure is greater (immediately) postpartum rather than during the intrapartum period, although it is possible that intrapartum events could contribute to the later development of pulmonary oedema. 7, 8 Additionally, although a restricted second stage is often advised antenatally, women often end up with a longer active second stage than recommended, even women with more severe forms of heart disease (modified WHO score 3 and 4). Despite this, no adverse events such as arrhythmia, chest pain or heart failure have been reported. 9 Electively shortening the duration of the active phase of the second stage increases the number of women having an instrumental delivery 9 ; in one large series of 559 women with cardiac disease, nearly one-third had an assisted delivery to minimise maternal expulsive efforts. 10 In women without heart disease, assisted delivery is associated with greater perineal trauma and a higher rate of third degree tears.
11 Similar findings were reported in a study of 65 women with cardiac disease in whom 72% had an instrumental delivery and experienced a significantly increased risk of both PPH and third and fourth degree tears. 12 A Cochrane review suggests that in women without heart disease, a ventouse delivery is associated with less third or fourth degree tearing (with or without episiotomy), vaginal trauma, use of general anaesthesia, and flatus incontinence or altered continence. 13 This may suggest that a ventouse is preferable to a forceps delivery in women with cardiac disease; however, this has not been formally investigated.
At present no studies have evaluated the underlying cardiovascular changes that occur in labouring women with cardiac disease. Work from Robson et al. 6 demonstrated that in a small number of healthy women, cardiac output progressively increased in labour, reaching a peak at 8 cm, but the effects in pregnancy in women with cardiac disease remain largely unknown. It is critical that data are obtained on the maternal haemodynamics in the second stage of labour in women with heart disease so that we can understand the impact of repeated Valsalva manouevres and so give evidenced-based advice.
Third stage of labour and antibiotic prophylaxis
We have no data to guide our management of the third stage of pregnancy and the use of antibiotic prophylaxis. Rates of PPH in women with cardiac disease have been reported to be as high as 23%, with uterine atony being the single largest cause.
3 This is probably due to the cautious use of uterotonics as suggested by current guidelines, which advise the use of 2 IU of oxytocin 1 due to its negative inotropic and positive chronotropic effects. This advice is supported by a recent study on the impact of a 2-unit infusion of oxytocin given over 10 minutes in addition to a standard low dose infusion; women receiving the additional 2 IU infusion had a lower estimated blood loss at delivery (849 versus 505 ml).
14 There was no evidence of arrhythmia, ST segment change or alteration in maternal haemodynamics (blood pressure, heart rate, mean arterial blood pressure). These data suggest that a 2-unit infusion of oxytocin given over 10 minutes is safe and effective, but further studies are needed to prove this and to evaluate the use of larger doses of oxytocin. Current guidance states that antibiotic prophylaxis is unnecessary in the vast majority of situations and particularly after delivery (vaginal or caesarean). 1 However, since the introduction of this policy, the rate of infectious endocarditis in the UK has risen; 15 however, studies in pregnancy are lacking, again highlighting the need for greater research.
Conclusion
Current guidance for the management of labour and delivery in women with cardiac disease lacks a robust evidence base. The necessary information will only be provided by large collaborative studies that compare different management approaches for women with heart disease.
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